The fact that the synthetic Glo2 inhibitor, p-nitrocarbobenzoxyglutathione (p-NCBG), increases the cytotoxicity of doxorubicin in MCF7 cells further supports the idea that Glo2 may act as a survival factor for breast cancer cells. The gene discussed is HAGH; the disease is breast cancer.